KIKKOMAN CORPORATION
2801・Prime Market・Foods
Domestic Other Businesses
A group-support segment covering pharmaceuticals, chemical products, logistics, and indirect administrative services
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue (segment total) | ¥21,765 million | ¥21,566 million | ↑ |
| Revenue from external customers | ¥7,528 million | ¥7,424 million | ↑ |
| Inter-segment revenue | ¥14,236 million | ¥14,142 million | ↑ |
| Business profit | ¥1,627 million | ¥1,173 million | ↑ |
| Business profit margin | 7.5% | 5.4% | ↑ |
| Depreciation and amortization | ¥1,416 million | ¥1,856 million | ↓ |
| Capital expenditures | ¥1,374 million | ¥1,130 million | ↑ |
| Impairment loss | ¥0 million | ¥1,714 million | ↓ |
Business Details
This segment consolidates the Kikkoman Group's domestic non-food businesses. It manufactures and sells pharmaceuticals and chemical products such as clinical diagnostic enzymes, hygiene testing reagents, and hyaluronic acid, and also provides real estate leasing, transportation services, and indirect administrative services to group companies. Revenue from external customers was limited to ¥7,528 million, indicating that inter-segment transactions (¥14,236 million) form the core of the segment's group-service provision. In FY2026 (ending March 2026), clinical diagnostic enzymes, hygiene testing reagents, and hyaluronic acid all exceeded the prior-year period, driving both revenue and profit growth.
Recent Overview
Business profit margin improved sharply from 5.4% to 7.5% as the large prior-period impairment loss disappeared
In FY2026 (ending March 2026), the Domestic Other Businesses segment recorded revenue of ¥21,765 million (100.9% year-on-year) and business profit of ¥1,627 million (138.8% year-on-year), achieving growth in both revenue and profit. Clinical diagnostic enzymes, hygiene testing reagents, and hyaluronic acid exceeded the prior-year period, while the transportation business fell below it. The ¥1,714 million impairment loss recorded in the prior period was absent this period, causing the business profit margin to improve significantly from 5.4% to 7.5%. Depreciation and amortization also decreased from ¥1,856 million to ¥1,416 million.
Key Products
Growth Drivers
- Revenue growth driven by expanding demand for clinical diagnostic enzymes and hygiene testing reagents
- Stable internal demand for indirect administrative services (shared services) provided to group companies
- Continued expansion of demand for chemical products such as hyaluronic acid in the pharmaceutical and cosmetics markets
- Increased demand for shared services accompanying the Group's overall business expansion
Risks
- Risk of profit pressure in the transportation business from rising fuel and labor costs
- High dependence on intra-group services, creating risk of declining internal demand if the Group's overall business contracts
- Limited revenue from external customers (¥7,528 million), leaving little room for growth in external markets
- Future impairment risk from declining profitability of held assets (an impairment loss of ¥1,714 million was recorded in the prior period)
Last updated: June 19, 2026